Due to the frequency of genetic aberrations that increase activity in the PI3K-Akt-mTOR pathway, there is a rationale for directly targeting frequently mutated mediators of this pathway to control the progression of HNSCC, including Class I PI3K catalytic subunits [15]. This evidence concerns the gene PIK3CG and head and neck squamous cell carcinoma.